Bone Mets
Monitoring bone health and ensuring adequate calcium and vitamin D intake in postmenopausal women who are taking exemestane for the primary prevention of breast cancer is essential.
Oncology & Biotech News > Clinical Trial Reports
Targeting the bone microenvironment appears to be a potential approach to treating prostate cancer.
Oncology & Biotech News > Conference Highlights
While pertuzumab is moving ahead in the FDA approval process, an additional indication for denosumab might be halted.
Upfront zoledronic acid is superior to delayed use in postmenopausal women with early breast cancer who are being treated with the aromatase inhibitor letrozole.
Oncology & Biotech News > Breast Cancer
Antiresorptive medicines used to reduce the loss of bone mass related to bone metastases or treatment toxicity are associated with an increased risk of ONJ.
OncLive Nursing > Conference Highlights
Bone disease occurs in about 84% of patients with multiple myeloma and is responsible for a great deal of morbidity, including pain, hypercalcemia, compromised quality of life, and pathological fracture.
Oncology & Biotech News > Conference Highlights
A single dose of radiotherapy and a single injection of ibandronate provided similar pain relief from bone metastases in men with metastatic prostate cancer.
Oncology & Biotech News > Conference Highlights
Physicians and patients with castration-resistant prostate cancer (CRPC) have an increasing number of treatment options that improve outcomes.
Oncology & Biotech News > Conference Highlights
The impact that the tumor microenvironment has on the survival and growth of cancer cells is becoming increasingly well defined on several fronts.
Oncology Live > Specialty Focus
Inhibiting the RANKL protein, which is involved in bone metabolism, can delay the onset of the bone metastases in men with castration-resistant prostate cancer.
Two trials are underway that not only address bone-related issues but might improve survival rates for patients.
Investigational drug that emits alpha radiation shows significant improvement in overall survival.
Conferences > The 2011 European Multidisciplinary Cancer Congress
Fewer cancer patients need to be treated with denosumab to prevent one skeletal-related event due to bone metastases from solid tumors.
Oncology & Biotech News > Conference Highlights
It is estimated that approximately 80% of all patients with diagnoses of breast cancer, prostate cancer, or multiple myeloma will develop bone metastases at some time during the course of their disease.
Contemporary Oncology > Articles
The use of denosumab to prevent SREs in men with mCRPC has questionable cost-effectiveness as compared with zoledronic acid.
Oncology & Biotech News > Conference Highlights
A pivotal phase III study found that men with CRPC experienced prolonged bone metastasis–free survival with Xgeva versus placebo.
Prostate cancer metastases, or cancer growing outside the prostate glands, can occur in any organ but is seen most frequently in the bone.
This informative video explains why bone health is so vital for cancer patients.
Therapies that target bone metastases have been developed for more than a decade.
Oncology & Biotech News > Conference Highlights
Cabozantinib (XL184), a novel tyrosine kinase inhibitor, caused the deaths of 6 patients in a phase II clinical trial.
Conferences > 2011 ASCO Annual Meeting
External Resources
American Journal of Managed Care
HCPLive
PainLive
Pharmacy Times
Physicians' Education Resource
Physician's Money Digest
American Journal of Managed Care
HCPLive
PainLive
Pharmacy Times
Physicians' Education Resource
Physician's Money Digest
Intellisphere, LLC
666 Plainsboro Road
Building 300
Plainsboro, NJ 08536
P: 609-716-7777
F: 609-716-4747
Copyright HCPLive 2006-2012
Intellisphere, LLC. All Rights Reserved.
666 Plainsboro Road
Building 300
Plainsboro, NJ 08536
P: 609-716-7777
F: 609-716-4747
Copyright HCPLive 2006-2012
Intellisphere, LLC. All Rights Reserved.